Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders [1] - The company aims to redefine psychiatry by leveraging neurobiology to create personalized and effective treatment options [1] Upcoming Investor Conferences - Alto Neuroscience will participate in the TD Cowen 46th Annual Healthcare Conference from March 2-5, 2026, with a presentation scheduled for March 3, 2026, at 1:50 pm EST [1] - The company will also attend the Jefferies 2026 Biotech on the Beach Summit on March 10-11, 2026, focusing on one-on-one investor meetings [1] - Presentations will be accessible via a live webcast on Alto's investor relations website, with replays available afterward [1] Clinical Development - Alto Neuroscience has completed patient enrollment in its Phase 2 proof-of-concept clinical trial for ALTO-101, a transdermal phosphodiesterase-4 (PDE4) inhibitor targeting cognitive impairment associated with schizophrenia [1] - The company’s clinical-stage pipeline includes novel drug candidates for depression, schizophrenia, and other mental health conditions [1] Intellectual Property - Alto Neuroscience has strengthened its intellectual property portfolio with the issuance of U.S. Patent Number 12,521,374, which covers methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron [1] - This patent protects the use of ondansetron to mitigate side effects related to pramipexole in the treatment of depression [1]

BLFC Sensory Room Image of future sensory Collegium Pharmaceutical Sensory Room for BLFC home matches Scoreboard for BLFC Scoreboard at BLFC Matches at White Stadium with Collegium Branding BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are w ...

Core Insights - Charles River Laboratories International, Inc. (CRL) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.39, a decrease of 10.2% year over year, but exceeded the Zacks Consensus Estimate by 2.51% [1] - On a GAAP basis, the company reported a loss of $5.62 per share compared to a loss of $4.22 in the same quarter last year [1] - Full-year 2025 EPS was $10.28, down 0.4% from the previous year, but surpassed the Zacks Consensus Estimate by 0.6% [1] Revenue Performance - Revenues for the fourth quarter totaled $994.2 million, beating the Zacks Consensus Estimate by 0.84%, but fell 0.8% from the previous year [2] - Full-year 2025 revenues were $4.02 billion, a decrease of 0.9% from the prior year, yet exceeded the Zacks Consensus Estimate by 0.2% [2] Segment Performance - Research Models and Services (RMS) revenues were $206.3 million, up 1% year over year, but down 0.9% organically [4] - Discovery and Safety Assessment (DSA) revenues amounted to $591.6 million, down 2% year over year and 3.3% organically [5] - Manufacturing Solutions revenues totaled $196.4 million, up 0.7% year over year, but down 2.1% organically [5] Margin Performance - Gross profit for the quarter was $414.4 million, an increase of 8.8% from the prior year, with a gross margin of 41.7%, up 368 basis points year over year [7] - Adjusted operating profit was $218.3 million, reflecting a 17.8% increase from the previous year, with an adjusted operating margin of 22%, up 347 basis points [7] Liquidity Position - At the end of the fourth quarter, cash and cash equivalents were $213.8 million, up from $194.6 million at the end of 2024 [10] - Cumulative net cash provided by operating activities was $737.6 million, compared to $734.6 million a year ago [10] 2026 Guidance - The company expects total revenues for 2026 to be at least flat to 1.5% growth, with the Zacks Consensus Estimate for 2025 revenues at $4.07 billion, implying 1.6% growth [11] - Adjusted EPS for 2026 is projected to be in the range of $10.70-$11.20, with the Zacks Consensus Estimate at $10.59 [11] Overall Assessment - CRL's fourth-quarter results showed earnings and revenues beating estimates, with significant improvement in DSA net bookings, indicating stabilization in biopharmaceutical demand [12] - The expansion of both gross and adjusted operating margins is viewed positively, and management is cautiously optimistic about continued positive demand trends in 2026 [12]

On February 17, 2026, Rock Springs Capital Management disclosed a buy of 46,497 shares of Kymera Therapeutics (NASDAQ:KYMR), with the estimated transaction value at $3.14 million based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Rock Springs Capital Management LP increased its stake in Kymera Therapeutics by 46,497 shares. The estimated transaction value for the quarter was $3.14 million, based on the average closing ...

Poxel Reports its 2025 Revenue and Provides an Update on its Financial PositionFeb 16, 2026 1:02 PM Eastern Standard Time# Poxel Reports its 2025 Revenue and Provides an Update on its Financial PositionShare---- As at 31 December 2025, cash and cash equivalents amounted to €0.9 million.- Poxel generated revenue of €5.0 million for the year ended 31 December 2025 corresponding to 10% royalties on TWYMEEG net sales- Gross sales of TWYMEEG® in Japan continued to accelerate, increasing by 15.0% in the fourth qu ...

As filed with the U.S. Securities and Exchange Commission on February 13, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ping An Biomedical Co., Ltd. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification Number) 22/F, China United Plaza 1002-1008, Tai Nan West Street Cheung Sha Wan, Kowloon Hong Kong +852 3915 2600 (Address, including zip code, and telephone ...

Core Insights - BioVie Inc is focusing on addressing the root causes of neurodegeneration, particularly in Parkinson's disease, rather than just treating symptoms [1][4][12] Company Overview - BioVie Inc is a clinical-stage biopharmaceutical company with a market capitalization in the tens of millions [1] - The company is advancing bezisterim (NE3107), an oral small-molecule drug aimed at blocking TNF alpha mediated inflammation and reversing insulin resistance [2] Parkinson's Disease Focus - Parkinson's disease affects approximately one million people in the U.S., with prevalence expected to rise as the population ages [3] - Current treatments, primarily Levodopa, do not slow neurodegeneration and can lead to involuntary movements [3] - BioVie posits that Parkinson's symptoms arise from low dopamine levels and chronic inflammation due to insulin resistance [4] Clinical Trials and Data - BioVie has completed enrollment in the SUNRISE-PD trial, evaluating bezisterim in 60 early-stage Parkinson's patients not yet on levodopa therapy [6] - The trial aims to determine if bezisterim can delay motor decline, differentiating it from existing treatments [6] - Topline data from the SUNRISE-PD trial is expected in April or May 2026, marking a significant catalyst for the company [7] Broader Implications of Bezisterim - Beyond Parkinson's, bezisterim is also being studied for long COVID and Alzheimer's disease, where chronic inflammation plays a role [8] - A 200-patient trial for long COVID is underway, supported by a $13 million non-dilutive grant [8] Additional Clinical Asset - BioVie is also advancing BIV201, targeting ascites associated with late-stage liver disease, with a Phase 2 trial showing over 50% reduction in fluid buildup [9] - The program has received FDA clearance to proceed directly into a Phase 3 study under orphan and fast-track designations [9] Market Position and Investment Outlook - Despite a broad clinical portfolio, BioVie’s valuation remains modest, attributed to market skepticism towards early-stage biotech [10] - The company presents a high-risk, high-reward investment opportunity with multiple catalysts expected in the next 12 to 18 months [11] - 2026 is anticipated to be a significant year for the company, with potential for substantial market impact if clinical data supports its hypotheses [11][12]

Core Viewpoint - CIMG Inc. announced the acquisition of Daren Business Technology Limited through its subsidiary DZR Tech Limited, aiming to enhance its digital health and sales development capabilities [1] Group 1: Acquisition Details - DZR Tech Limited entered into a definitive share purchase agreement on February 5, 2026, to acquire 100% of the equity interests in Daren Business Technology Limited [1] - The transaction is contingent upon the completion of customary closing conditions, including satisfactory due diligence [1]

Core Insights - The article discusses the integration of AI into a conservative investment strategy, focusing on building a sustainable portfolio system rather than chasing high returns [2][4][38] Investment Strategy Structure - The investment approach utilizes a "barbell" strategy at multiple levels, encompassing a wide range of assets including business interests, private placements, real estate, and investable cash [5] - The investable cash is allocated with 80% in treasuries and high-quality bonds, 15% in dividend aristocrats and quality compounders, and 5% in speculative portfolios [6] Speculative Portfolios - Five speculative themes are identified: space technology, AI in biopharmaceutical discovery, quantum computing, energy/grid resilience, and biomedical companies poised for acquisition [7][17][18][19][20][21] - Each speculative portfolio follows a "mini-ETF" structure, consisting of 10-15 holdings categorized by company size and revenue generation [13] AI Contributions - AI has been instrumental in creating a structured documentation hierarchy for the investment strategy, ensuring clarity and accessibility for future management [9][10][11] - AI assists in developing company filters and screening criteria, ensuring that selected companies meet specific requirements for investment [14][15][16] Performance Modeling - AI helps model the contribution of speculative portfolios to overall returns, aiming for a modest inflation-plus return rather than market-beating performance [24][25][26] - The speculative allocation is designed to provide a potential uplift to the overall portfolio, with a focus on maintaining discipline in position sizing [27][28] Monitoring and Refinement - AI aids in refining portfolio structure by identifying inconsistencies and gaps, as well as tracking relevant metrics for each portfolio [29][30] - Weekly news digests generated by AI keep the investor informed about developments in the speculative holdings, streamlining the research process [31] Intellectual Engagement - The investment strategy allows for continued engagement in fields of interest, providing a structured approach to speculative investing that is intellectually stimulating [34][35][36] - The use of AI enhances the sustainability of this engagement, making it easier to stay informed and organized [37]

Company Overview - Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing next-generation peptide-based therapeutics for metabolic and liver diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH) [4] - The lead candidate, pemvidutide, targets GLP-1 and glucagon receptors to reduce weight, liver fat, and cardiometabolic risk [4] Analyst Support and Market Outlook - Barclays initiated coverage of ALT with an Overweight rating and a $20 price target, citing strong underlying fundamentals and continuous merger and acquisition activity as reasons for optimism in the biotech industry by 2026 [2] - The firm also noted that ALT and other biotech stocks remain undervalued compared to their pipeline potential [2] Recent Developments - Altimmune announced plans to use net proceeds from a recent offering for working capital and preparation for its next Phase 3 MASH research [3] - The company received FDA's Breakthrough Therapy Designation and reported positive Phase 2b 48-week findings for pemvidutide, reinforcing its potential as a novel glucagon/GLP-1 dual agonist [3]